64P Molecularly unselected immune-based versus non-immune-based trials: Outcomes in refractory metastatic castrate resistant prostate cancer (mCPRC) at Sarah Cannon Research Institute (SCRI) UK
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Fields of Study & Subjects
Prostate Cancer Treatment and Research
Cancer Immunotherapy and Biomarkers
Prostate Cancer Diagnosis and Treatment
Publication details
- Journal / source
- ESMO Open
- Volume
- 11
- Pages
- 106205–106205
- Publication date
- 1 April 2026
- Language
- EN